Oyster Point Pharma Stock News

Conference Call and Webcast Scheduled for February 24, 2022, 4:30 p.m. ET Conference Call and Webcast Scheduled for February 24, 2022, 4:30 p.m. ET

Conference Call and Webcast Scheduled for February 24, 2022, 4:30 p.m. ET Conference Call and Webcast Scheduled for February 24, 2022, 4:30 p.m. ET

Oyster Point Pharma Inc (OYST) shares closed today 14.7% lower than it did at the end of yesterday. The stock is currently down 28.5% year-to-date, down 28.7% over the past 12 months, and down 30.5% over the past five years. Today, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.4%. Trading Activity Shares traded as high as $16.61 and as low as $12.96 this week.Shares closed 49.6% below its 52-week high and 32.4% above its 52-week low.Trading volume this week was 32.1% lower than the 10-day average and 44.7% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 947.7% The company's stock price performance over the past 12 months beats the peer average by -5.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

PRINCETON, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization

PRINCETON, N.J., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercializatio

PRINCETON, N.J., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the Company will participate virtually in the following upcoming investor conferences:

PRINCETON, N.J., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization

PRINCETON, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that Oyster Point Pharma will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, December 20 th .

PRINCETON, N.J., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercializatio

PRINCETON, N.J., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that the Company will participate virtually in the Piper Sandler 33 rd Annual Healthcare Conference on Thursday, December 2, 2021. Presentations are available for registered attendees via the Piper Sandler conference site

Ardelyx, Inc. (ARDX) with the stream of -3.41% also noticed, India Oyster Point Pharma, Inc. (OYST) encountered a rapid change of -2.37% in the last hour of Mondays trading session. The post Beholding Stock: Ardelyx, Inc. (NASDAQ:ARDX), Oyster Point Pharma, Inc. (NASDAQ:OYST) appeared first on Stocks Equity .

Fujian Blue Hat Interactive Entertainment Technology Ltd. (BHAT) with the stream of 1.82% also noticed, India Oyster Point Pharma, Inc. (OYST) encountered a rapid change of 0.47% in the last The post Buy or Sell? What Analysts Recommends: Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ:BHAT), Oyster Point Pharma, Inc. (NASDAQ:OYST) appeared first on Stocks Equity .

PRINCETON, N.J., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization

PRINCETON, N.J., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced the promotion of Barry Rosenfeld, JD as General Counsel, and Raegan A. McClain, JD, LLM, CCEP as Chief Compliance offer, both of whom will join the executive leadership team.

Oyster Point Pharma, Inc. (NASDAQ:OYST) saw a large increase in short interest in the month of October. As of October 29th, there was short interest totalling 1,390,000 shares, an increase of 98.0% from the October 14th total of 702,000 shares. Based on an average daily volume of 360,000 shares, the days-to-cover ratio is presently 3.9 […]